NCT03593408 Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support
| NCT ID | NCT03593408 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Drug Effect |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2019-02-08 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2019-02-08 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will measure plasma concentrations of dexmedetomidine, fentanyl, morphine and midazolam in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to understand the pharmacokinetics of these drugs in this setting.
Eligibility Criteria
Inclusion Criteria: * supported on ECMO * receiving one or a combination of the following drugs dexmedetomidine, fentanyl, midazolam or morphine as part of sedation management Exclusion Criteria: -none
Contact & Investigator
Viviane Nasr, MD
PRINCIPAL INVESTIGATOR
Boston Children's Hospital
Frequently Asked Questions
Who can join the NCT03593408 clinical trial?
This trial is open to participants of all sexes, aged 0 Days or older, up to 17 Years, studying Drug Effect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03593408 currently recruiting?
Yes, NCT03593408 is actively recruiting participants. Contact the research team at viviane.nasr@childrens.harvard.edu for enrollment information.
Where is the NCT03593408 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03593408 clinical trial?
NCT03593408 is sponsored by Boston Children's Hospital. The principal investigator is Viviane Nasr, MD at Boston Children's Hospital. The trial plans to enroll 20 participants.